The Food and Drug Administration (FDA) conducted an inspection at Octapharma Plasma, Inc. in Denver on March 19 to review blood and blood products, according to information available on the FDA’s website.
The final report concluded that Octapharma Plasma, Inc. did not require any corrective actions regarding the organization’s operational management.
The FDA regularly conducts facility inspections nationwide to verify that worksites and their products comply with FDA-regulated standards and regulations intended to promote public health. The agency publicly discloses outcomes of these inspections.
The agency’s official website states the FDA is the governing body tasked with overseeing the safety and quality of human and animal drugs, biological products, medical equipment, and tobacco products.
Information for this article was sourced from the U.S. Food and Drug Administration. To access the original data, click here.
